Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
July 30, 2026
Oncocyte Presents Confirmatory Data for DetermaIO(TM) at the American Association for Cancer Research Annual Meeting 2022
April 11, 2022
Related Post
-
-
Curis Doses First Five Patients in TakeAim CLL Study
July 30, 2026
-
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
July 29, 2026
-
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
July 27, 2026